Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957786 | 1.00 | ERN1 (0.57) | ERN1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL269702 | 0.82 | TDP1 (0.61) | ERN1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL22171539 | 0.81 | CYP3A4 (0.50) | ERN1TDP1ALDH1A1CYP3A4TP53 | |
| SCHEMBL11664145 | 0.79 | ERN1 (0.41) | ERN1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL11664142 | 0.79 | ERN1 (0.41) | ERN1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL28030980 | 0.79 | CYP3A4 (0.48) | ERN1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL4357334 | 0.78 | TDP1 (0.70) | ERN1TDP1ALDH1A1HPGDTP53 | |
| SCHEMBL2559192 | 0.78 | RAPGEF4 (0.51) | ERN1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL7820969 | 0.77 | CYP3A4 (0.46) | ERN1TDP1ALDH1A1CYP3A4TP53 | |
| SCHEMBL6258762 | 0.77 | CYP3A4 (0.46) | ERN1TDP1ALDH1A1CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831253-B | Pendimethalin hapten as well as preparation method and application thereof | 南京农业大学 | 2023-07-04 | — | — | CN | claimed |
| CN-113831253-A | Pendimethalin hapten as well as preparation method and application thereof | 南京农业大学 | 2021-12-24 | — | — | CN | claimed |
| CN-111253223-A | Triarylmethane derivatives with large steric hindrance and synthesis method thereof | 重庆医科大学 | 2020-06-09 | — | — | CN | claimed |
| CN-1029680-C | Process for synthesizing benzfluorenol as antimalarial | INST OF MICROBIOLOGY & EPIDEMI (CN) | 1995-09-06 | — | — | CN | claimed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025059417-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-113979835-B | Synthesis method of pazopanib trimer impurity intermediate | 重庆医科大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-113979835-B | Synthesis method of pazopanib trimer impurity intermediate | 重庆医科大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-113831253-B | Pendimethalin hapten as well as preparation method and application thereof | 南京农业大学 | 2023-07-04 | — | — | CN | disclosed |
| US-20230167089-A1 | ORGANIC MATERIAL COMPOSITION AND APPLICATIONS THEREOF | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-6350749-B1 | SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| US-6242493-B1 | PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-06-05 | — | — | US | disclosed |
| CN-1290249-A | Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
| EP-1071648-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Frosst Canada & Co. (CA) | 2001-01-31 | — | — | EP | disclosed |
| EP-1057812-A1 | AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0950418-A2 | Composition for preventing or treating ischemic disease | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999047497-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 1999-09-23 | — | — | WO | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167089-A1 | ORGANIC MATERIAL COMPOSITION AND APPLICATIONS THEREOF | PIEZO1, VCL, VDAC3 | ERN1 2498/4885TDP1 1585/4885ALDH1A1 2385/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ERN1 874/4885TDP1 1596/4885ALDH1A1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.